This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): prGCD, taliglucerase alfa, Uplyso, alfataliglicerase
Description: prGCD is a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD) that uses the Protalix's ProCellEx protein expression system which produced recombinant proteins that exhibit a glycan and amino acid structure similar to their naturally-produced human counterparts.
Revenue splits for this drug are BioMedTracker estimates.
Pfizer and Protalix
In December 2009, Pfizer and Protalix announced that they entered into an agreement to develop and commercialize taliglucerase alfa in development for the potential treatment of Gaucher's disease. Under the terms of the agreement, Pfizer will receive exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while Protalix will retain the exclusive commercialization rights in Israel.
Under the agreement, Pfizer will make an upfront payment of $60 million to Protalix. In addition, Protalix is eligible to receive additional regulatory milestone payments of up to $55 million. Pfizer and Protalix will share future revenues and expenses for the development and commercialization of taliglucerase alfa on a 60 percent/40 percent basis respectively.
In December 2012, Protalix entered into a Clinical Development Agreement with Pfizer under which Protalix will...See full deal structure in Biomedtracker
Partners: Protalix BioTherapeutics, Inc.
Additional information available to subscribers only: